Andrew is Director Clinical Science in the Emerging Innovations (EI) team at AstraZeneca. He is the Medical Lead for the EI team and lends his scientific and clinical expertise to drug development & drug repurposing projects spanning target identification through to phase 2 clinical trials. Andrew works closely with David Weston to identify and evaluate pioneering new technologies in the areas of biopharmaceuticals, healthcare and life-sciences.
Prior to joining AstraZeneca in 2016, Andrew was a Consultant Cardiologist in the UK National Health Service. He graduated from University of Leicester Medical School with honours in 2000, and went on to receive a Doctorate in Medicine in 2008 for his research into endothelial progenitor cells under the supervision of Sir Prof Nilesh Samani. Andrew also worked in Medical Affairs at Servier in the mid-2000s with responsibility for their CV risk portfolio.